ReviewTranslational research : the journal of laboratory and clinical medicine2021
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease.
Review in Translational research : the journal of laboratory and clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.International journal of clinical practice · 2022Pooled it
- Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.RMD open · 2023Trial
- A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2023Trial
- Systemic lupus erythematosus-related mortality declined but disparities persisted in the United States: a nationwide multiple-cause-of-death analysis, 1999-2023.Frontiers in immunology · 2026Observational
- Lupus Nephritis During the COVID-19 Pandemic: Challenges and Implications Before, During, and After.Biomedicines · 2025Article
- Long-Term Effects of COVID-19 on Women's Reproductive Health and Its Association with Autoimmune Diseases, Including Multiple Sclerosis.Journal of clinical medicine · 2025Review
- Article
- A Study on Semaphorin 3A Level in Juvenile-onset Systemic Lupus Erythematosus Patients.Current rheumatology reviews · 2025Article
- SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021.Lupus science & medicine · 2024Article
- Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection.QJM : monthly journal of the Association of Physicians · 2024Article
- Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk.Molecular medicine (Cambridge, Mass.) · 2024Article
- Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization.Clinical and experimental medicine · 2024Article
- Systemic Lupus Erythematosus and Cytokine Storm.Advances in experimental medicine and biology · 2024Review
- Observational
- Knowledge mapping of COVID-19 and autoimmune diseases: a visual and bibliometric analysis.Clinical and experimental medicine · 2023Article
- Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression.European journal of rheumatology · 2023Article
- COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology.Lupus science & medicine · 2023Observational
- Disparities in Lupus and the Role of Social Determinants of Health: Current State of Knowledge and Directions for Future Research.ACR open rheumatology · 2023Review
- Systemic lupus erythematosus nephritis and COVID-19 disease.Clinical rheumatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a growing need to assess its impact in patients with autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). Patients with SLE are a unique population when considering the risk of contracting COVID-19 and infection outcomes. The use of systemic glucocorticoids and immunosuppressants, and underlying organ damage from SLE are potential susceptibility factors. Most patients with SLE have evidence of high type I interferon activity, which may theoretically act as an antiviral line of defense or contribute to the development of a deleterious hyperinflammatory response in COVID-19. Other immunopathogenic mechanisms of SLE may overlap with those described in COVID-19, thus, studies in SLE could provide some insight into immune responses occurring in severe cases of the viral infection. We reviewed the literature to date on COVID-19 in patients with SLE and provide an in-depth review of current research in the area, including immune pathway activation, epidemiology, clinical features, outcomes, and the psychosocial impact of the pandemic in those with autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.